A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...
🛍️ Amazon Big Spring Sale: 100+ editor-approved deals worth buying right now 🛍️ By Amy Shira Teitel Published Apr 1, 2016 11:46 PM EDT Add Popular Science (opens in a new tab) Adding us as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results